Skip to main content
PMC home page
Gut logoLink to Gut
. 1998 Feb;42(2):166–169. doi: 10.1136/gut.42.2.166

Influence of metronidazole resistance on efficacy of quadruple therapy for Helicobacter pylori eradication

R W M van der Hulst 1, A van der Ende 1, A Homan 1, P Roorda 1, J Dankert 1, G Tytgat 1
PMCID: PMC1727013  PMID: 9536938

Abstract

Background—Metronidazole-containing eradication therapies are less effective for metronidazole resistant Helicobacter pylori. Although early data suggested improvement of the efficacy of bismuth triple therapy after the addition of acid suppressives, these findings were based on studies with small numbers of patients, incomplete post-eradication follow up, or omission of pretreatment susceptibility testing. 
Aims—To study the efficacy of quadruple therapy in the Amsterdam area, where the efficacy of bismuth triple therapy has been proved to be affected by metronidazole resistance. 
Patients and methods—Eighty two consecutive dyspeptic H pylori positive patients with either metronidazole susceptible (group I) or metronidazole resistant H pylori strains (group II) received quadruple therapy for one week: omeprazole 20 mg twice daily; colloidal bismuth subcitrate 120 mg four times a day; tetracycline 500 mg four times a day; metronidazole 500 mg three times a day. Susceptibility to metronidazole was determined by the E-test. 
Results—Intention to treat analysis showed that H pylori infection had been cured in 42/43 patients (98%) in group I and 32/39 patients (82%) in group II (p = 0.02). 
Conclusion—The efficacy of quadruple therapy is significantly impaired in patients infected with metronidazole resistant H pylori. Therefore a non-metronidazole-containing regimen should preferably be used in areas known to have a high prevalence of pretreatment metronidazole resistance. 



Keywords: quadruple therapy; metronidazole resistance; Helicobacter pylori; gastritis; duodenal ulcer disease

Full Text

The Full Text of this article is available as a PDF (88.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Borody T. J., Andrews P., Fracchia G., Brandl S., Shortis N. P., Bae H. Omeprazole enhances efficacy of triple therapy in eradicating Helicobacter pylori. Gut. 1995 Oct;37(4):477–481. doi: 10.1136/gut.37.4.477. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Cederbrant G., Kahlmeter G., Ljungh A. Proposed mechanism for metronidazole resistance in Helicobacter pylori. J Antimicrob Chemother. 1992 Feb;29(2):115–120. doi: 10.1093/jac/29.2.115. [DOI] [PubMed] [Google Scholar]
  3. Crespo I., Murphy J., Wong R. K. Superior mesenteric venous thrombosis masquerading as Crohn's disease. Am J Gastroenterol. 1994 Jan;89(1):116–118. [PubMed] [Google Scholar]
  4. Edwards D. I. Nitroimidazole drugs--action and resistance mechanisms. I. Mechanisms of action. J Antimicrob Chemother. 1993 Jan;31(1):9–20. doi: 10.1093/jac/31.1.9. [DOI] [PubMed] [Google Scholar]
  5. Graham D. Y., Lew G. M., Malaty H. M., Evans D. G., Evans D. J., Jr, Klein P. D., Alpert L. C., Genta R. M. Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology. 1992 Feb;102(2):493–496. doi: 10.1016/0016-5085(92)90095-g. [DOI] [PubMed] [Google Scholar]
  6. Hosking S. W., Ling T. K., Yung M. Y., Cheng A., Chung S. C., Leung J. W., Li A. K. Randomised controlled trial of short term treatment to eradicate Helicobacter pylori in patients with duodenal ulcer. BMJ. 1992 Aug 29;305(6852):502–504. doi: 10.1136/bmj.305.6852.502. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Noach L. A., Langenberg W. L., Bertola M. A., Dankert J., Tytgat G. N. Impact of metronidazole resistance on the eradication of Helicobacter pylori. Scand J Infect Dis. 1994;26(3):321–327. doi: 10.3109/00365549409011802. [DOI] [PubMed] [Google Scholar]
  8. Penston J. G. Review article: Helicobacter pylori eradication--understandable caution but no excuse for inertia. Aliment Pharmacol Ther. 1994 Aug;8(4):369–389. doi: 10.1111/j.1365-2036.1994.tb00304.x. [DOI] [PubMed] [Google Scholar]
  9. Smith M. A., Edwards D. I. Redox potential and oxygen concentration as factors in the susceptibility of Helicobacter pylori to nitroheterocyclic drugs. J Antimicrob Chemother. 1995 Jun;35(6):751–764. doi: 10.1093/jac/35.6.751. [DOI] [PubMed] [Google Scholar]
  10. Van der Hulst R. W., Tytgat G. N. Helicobacter pylori and peptic ulcer disease. Scand J Gastroenterol Suppl. 1996;220:10–18. [PubMed] [Google Scholar]
  11. Wallmark B., Brändström A., Larsson H. Evidence for acid-induced transformation of omeprazole into an active inhibitor of (H+ + K+)-ATPase within the parietal cell. Biochim Biophys Acta. 1984 Dec 19;778(3):549–558. doi: 10.1016/0005-2736(84)90406-1. [DOI] [PubMed] [Google Scholar]
  12. Weel J. F., van der Hulst R. W., Gerrits Y., Tytgat G. N., van der Ende A., Dankert J. Heterogeneity in susceptibility to metronidazole among Helicobacter pylori isolates from patients with gastritis or peptic ulcer disease. J Clin Microbiol. 1996 Sep;34(9):2158–2162. doi: 10.1128/jcm.34.9.2158-2162.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. de Boer W., Driessen W., Jansz A., Tytgat G. Effect of acid suppression on efficacy of treatment for Helicobacter pylori infection. Lancet. 1995 Apr 1;345(8953):817–820. doi: 10.1016/s0140-6736(95)92962-2. [DOI] [PubMed] [Google Scholar]
  14. van der Hulst R. W., Keller J. J., Rauws E. A., Tytgat G. N. Treatment of Helicobacter pylori infection: a review of the world literature. Helicobacter. 1996 Mar;1(1):6–19. doi: 10.1111/j.1523-5378.1996.tb00003.x. [DOI] [PubMed] [Google Scholar]
  15. van der Hulst R. W., van der Ende A., Dekker F. W., Ten Kate F. J., Weel J. F., Keller J. J., Kruizinga S. P., Dankert J., Tytgat G. N. Effect of Helicobacter pylori eradication on gastritis in relation to cagA: a prospective 1-year follow-up study. Gastroenterology. 1997 Jul;113(1):25–30. doi: 10.1016/s0016-5085(97)70076-3. [DOI] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES